Skip to main content
Journal cover image

Multicenter trial of desirudin for the prophylaxis of thrombosis: an alternative to heparin-based anticoagulation (DESIR-ABLE).

Publication ,  Journal Article
Bergese, SD; Minkowitz, HS; Arpino, PA; Sane, DC; Levy, JH
Published in: Clin Appl Thromb Hemost
2013

Desirudin, a subcutaneously (SC) administered direct thrombin inhibitor, is indicated for prevention of venous thromboembolic events (VTEs) after total joint replacement surgery. DESIR-ABLE (multicenter trial of desirudin for the prophylaxis of thrombosis: an alternative to heparin-based anticoagulation) was a multicenter, open-label, single-arm study of hospitalized patients requiring VTE protection designed to extend the safety profile for desirudin to include a broad population of perioperative/critically ill patients. The primary end point was major bleeding. A total of 516 patients undergoing major surgery (378, 73%) or who were medically ill with prolonged immobility (138, 27%) were enrolled at 19 centers and received desirudin 15 mg Q12H. Many patients had high-risk features for bleeding and thrombosis such as thrombocytopenia (<100 x 10(9)/mL, n = 50), severe obesity (body mass index >35, n = 145), and renal impairment (creatinine clearance <60 mL/min, n = 292). There were no major bleeds and no VTE-related deaths in this study. The DESIR-ABLE demonstrated the safety of desirudin in critically ill perioperative and medical patients. Trials in specific surgical or medically ill patients are needed to confirm these findings.

Duke Scholars

Published In

Clin Appl Thromb Hemost

DOI

EISSN

1938-2723

Publication Date

2013

Volume

19

Issue

4

Start / End Page

418 / 423

Location

United States

Related Subject Headings

  • Young Adult
  • Thrombosis
  • Surgical Procedures, Operative
  • Recombinant Proteins
  • Middle Aged
  • Male
  • Humans
  • Hirudins
  • Heparin
  • Female
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Bergese, S. D., Minkowitz, H. S., Arpino, P. A., Sane, D. C., & Levy, J. H. (2013). Multicenter trial of desirudin for the prophylaxis of thrombosis: an alternative to heparin-based anticoagulation (DESIR-ABLE). Clin Appl Thromb Hemost, 19(4), 418–423. https://doi.org/10.1177/1076029612452779
Bergese, Sergio D., Harold S. Minkowitz, Paul A. Arpino, David C. Sane, and Jerrold H. Levy. “Multicenter trial of desirudin for the prophylaxis of thrombosis: an alternative to heparin-based anticoagulation (DESIR-ABLE).Clin Appl Thromb Hemost 19, no. 4 (2013): 418–23. https://doi.org/10.1177/1076029612452779.
Bergese SD, Minkowitz HS, Arpino PA, Sane DC, Levy JH. Multicenter trial of desirudin for the prophylaxis of thrombosis: an alternative to heparin-based anticoagulation (DESIR-ABLE). Clin Appl Thromb Hemost. 2013;19(4):418–23.
Bergese, Sergio D., et al. “Multicenter trial of desirudin for the prophylaxis of thrombosis: an alternative to heparin-based anticoagulation (DESIR-ABLE).Clin Appl Thromb Hemost, vol. 19, no. 4, 2013, pp. 418–23. Pubmed, doi:10.1177/1076029612452779.
Bergese SD, Minkowitz HS, Arpino PA, Sane DC, Levy JH. Multicenter trial of desirudin for the prophylaxis of thrombosis: an alternative to heparin-based anticoagulation (DESIR-ABLE). Clin Appl Thromb Hemost. 2013;19(4):418–423.
Journal cover image

Published In

Clin Appl Thromb Hemost

DOI

EISSN

1938-2723

Publication Date

2013

Volume

19

Issue

4

Start / End Page

418 / 423

Location

United States

Related Subject Headings

  • Young Adult
  • Thrombosis
  • Surgical Procedures, Operative
  • Recombinant Proteins
  • Middle Aged
  • Male
  • Humans
  • Hirudins
  • Heparin
  • Female